Author

Charlie Cruze

Institution: Bexion Pharmaceuticals (United States)

Observed institution: Bexion Pharmaceuticals (United States)

ORCID: 0009-0005-7279-0106

Observed ORCID: 0009-0005-7279-0106

OpenAlex ID: A5060308277

A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas

2024 · Olivier Rixe, John L. Villano, et al. · Clinical Cancer Research · 6

Abstract 3072: BXQ-350: A novel biologic that allosterically activates glucosylcerebrosidase and demonstrates signs of activity in cancer patients

2024 · Gilles H. Tapolsky, Charlie Cruze, et al. · Cancer Research · 1

Abstract 4437: BXQ-350: A novel biologic with an innovative mechanism of action targeting sphingolipid metabolism that induces cancer cell death and repolarizes the tumor microenvironment

2023 · Gilles H. Tapolsky, Tim Stephens, et al. · Cancer Research · 1

Supplementary Table S5 from A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas

2024 · Olivier Rixe, John L. Villano, et al.

Data from A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas

2024 · Olivier Rixe, John L. Villano, et al.

Supplementary Figure S2 from A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas

2024 · Olivier Rixe, John L. Villano, et al.

Supplementary Table S2 from A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas

2024 · Olivier Rixe, John L. Villano, et al.

Supplementary Figure S1 from A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas

2024 · Olivier Rixe, John L. Villano, et al.

Supplementary Table S1 from A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas

2024 · Olivier Rixe, John L. Villano, et al.

Supplementary Table S3 from A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas

2024 · Olivier Rixe, John L. Villano, et al.

Supplementary Methods S1 from A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas

2024 · Olivier Rixe, John L. Villano, et al.

Supplementary Table S4 from A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas

2024 · Olivier Rixe, John L. Villano, et al.

Abstract 3042: BXQ-350 may protect peripheral nerves from the direct cytotoxicity of chemotherapeutic agents leading to chemotherapy induced peripheral neuropathy

2023 · Nikhil Wilkins, Tim Stephens, et al. · Cancer Research

Works count: 13

Citation count: 8

H-index: 1

I10-index: